三氯(三氯甲氧基)甲烷 | 109575-85-1

• 分子结构分类: 有机化合物 - 有机卤素化合物 - 卤代烷
• 中文名称: 三氯(三氯甲氧基)甲烷
• 英文名称: bis-trichloromethyl ether
• 英文别名: Bis-trichlormethyl-aether；Perchlordimethylaether；Perchlordimethyloxyd；di-trichloromethyl ether；trichloromethyl ether；Trichloro(trichloromethoxy)methane
• CAS: 109575-85-1
• 化学式: C₂Cl₆O
• 分子量: 252.739
• InChiKey: SMYMDRJWEFCCCI-UHFFFAOYSA-N

物化性质

• 沸点：
  206.8±35.0 °C(Predicted)
• 密度：
  1.854±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  4
• 重原子数：
  9
• 可旋转键数：
  0
• 环数：
  0.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  9.2
• 氢给体数：
  0
• 氢受体数：
  1

反应信息

• 作为反应物：
  描述：

  三氯(三氯甲氧基)甲烷 生成 四氯化碳 、 光气
  参考文献：
  名称：

  de Sonay, Chemische Berichte, 27 Ref. <1894>,338

  摘要：

  DOI：
• 作为产物：
  描述：

  alkaline earth salt of/the/ methylsulfuric acid 在 氯 作用下， 生成 三氯(三氯甲氧基)甲烷
  参考文献：
  名称：

  Regnault, Justus Liebigs Annalen der Chemie, 1840, vol. 34, p. 30

  摘要：

  DOI：
• 作为试剂：
  描述：

  [2R,3R,4S,7R,8S,9R]-1-benzyloxy-3-[(tert-butyldimethylsilyl)oxy]-9-[(4-methoxybenzyl)oxy]-2,4,8,10-tetramethylundecan-7-ol-5-one 在 4-二甲氨基吡啶 、 三氯(三氯甲氧基)甲烷 、 氢氟酸 、 4-吡咯烷基吡啶 作用下， 以 乙腈 为溶剂， 生成 Acetic acid (2R,3S,4R,6R,9R,10R,11S)-10-hydroxy-2-isopropyl-3,9,11-trimethyl-1,7-dioxa-spiro[5.5]undec-4-yl ester
  参考文献：
  名称：

  合成bafilomycin A（1）的研究：构建C（13）-C25）段的片段组装醛醇缩合反应的立体化学方面。

  摘要：

  通过涉及手性醛6a和手性甲基酮7的片段组装醛醇缩合反应的途径，开发了对应于bafilomycin A（1）的C（13）-C（25）段的醛醇8a-c的高度立体选择性合成。在确定6a的关键醇醛偶联和7b的烯醇锂的立体选择性中，作用起关键作用。手性醛片段的C（23）-OH的保护基也会影响烯醇锂醛醇缩醛反应的选择性。相反，6a的醛醇缩合反应和7a，c的氯钛烯醇盐反应对C（15）-羟基保护基的性质的敏感度要低得多。还描述了手性醛与高井氏（γ-甲氧基烯丙基）铬试剂40的反应的研究。

  DOI：

  10.1021/jo016413f

文献信息

• Methods of treatment using an EP2 selective receptor agonist
  申请人：Constan A. Alexander

  公开号：US20050203086A1

  公开（公告）日：2005-09-15

  The present invention relates to methods of treating pulmonary hypertension, facilitating joint fusion, facilitating tendon and ligament repair, reducing the occurrence of secondary fracture, treating avascular necrosis, facilitating cartilage repair, facilitating bone healing after limb transplantation, facilitating liver regeneration, facilitating wound healing, reducing the occurrence of gastric ulceration, treating hypertension, facilitating the growth of tooth enamel or finger or toe nails, treating glaucoma, treating ocular hypertension, and repairing damage caused by metastatic bone disease using an EP 2 selective receptor agonist.

  本发明涉及使用EP2选择性受体激动剂治疗肺动脉高压、促进关节融合、促进肌腱和韧带修复、减少继发性骨折的发生、治疗缺血性坏死、促进软骨修复、促进肢体移植后的骨愈合、促进肝脏再生、促进伤口愈合、减少胃溃疡的发生、治疗高血压、促进牙齿珐琅质或手指甲和脚趾甲的生长、治疗青光眼、治疗眼高压以及修复由转移性骨疾病引起的损伤的方法。
• Iminothiadiazine Dioxide Compounds as BACE Inhibitors, Compositions and Their Use
  申请人：Merck Sharp & Dohme Corp.

  公开号：US20150307465A1

  公开（公告）日：2015-10-29

  In its many embodiments, the present invention provides certain iminothiadiazine dioxide compounds, including compounds Formula (I): and include stereoisomers thereof, and pharmaceutically acceptable salts of said compounds stereoisomers, wherein each of R 1 , R 2 , R 3 , R 4 , R 5 , R 9 , ring A, ring B, m, n, p, -L 1 -, -L 2 -, and -L 3 - is selected independently and as defined herein. The novel iminothiadiazine dioxide compounds of the invention have surprisingly been found to exhibit properties which are expected to render them advantageous as BACE inhibitors and/or for the treatment and prevention of various pathologies related to β-amyloid (“Aβ”) production. Pharmaceutical compositions comprising one or more such compounds (alone and in combination with one or more other active agents), and methods for their preparation and use in treating pathologies associated with amyloid beta (Aβ) protein, including Alzheimer's disease, are also disclosed.

  本发明提供了多种形式的亚氨基噻二唑二氧化物化合物，包括公式(I)的化合物： 包括它们的立体异构体，以及所述立体异构体的药用可接受盐，其中R1、R2、R3、R4、R5、R9、环A、环B、m、n、p、-L1-、-L2-和-L3-都是独立选择且按本文定义。发明的新型亚氨基噻二唑二氧化物化合物出人意料地被发现具有预期的特性，使其作为BACE抑制剂以及/或用于治疗和预防与β-淀粉样蛋白（“Aβ”）生成相关的各种病理学具有优势。还公开了包含一个或多个此类化合物（单独使用和与一个或多个其他活性成分组合使用）的药物组合物，以及它们的制备方法和用于治疗与淀粉样β（Aβ）蛋白相关的病理学，包括阿尔茨海默病的方法。
• Method and compositions for identifying anti-HIV therapeutic compounds
  申请人：Arimilli N. Murty

  公开号：US20050239054A1

  公开（公告）日：2005-10-27

  Methods are provided for identifying anti-HIV therapeutic compounds substituted with carboxyl ester or phosphonate ester groups. Libraries of such compounds are screened optionally using the novel enzyme GS-7340 Ester Hydrolase. Compositions and methods relating to GS-7340 Ester Hydrolase also are provided.

  提供了一种识别含有羧酸酯或磷酸酯基团取代的抗HIV治疗化合物的方法。可以选择使用新型酶GS-7340酯水解酶对这类化合物库进行筛选。还提供了与GS-7340酯水解酶相关的组合物和方法。
• PROPHYLACTIC AND/OR THERAPEUTIC AGENT FOR ANEMIA, COMPRISING TETRAHYDROQUINOLINE COMPOUND AS ACTIVE INGREDIENT
  申请人：Kowa Company, Ltd.

  公开号：EP2199283A1

  公开（公告）日：2010-06-23

  Disclosed is a low-molecular-weight compound having an EPO production-promoting activity and/or a hemoglobin expression-enhancing activity. Specifically disclosed is an EPO production promoter and/or a hemoglobin expression enhancer comprising a 1-acyl-4-(phenoxy, benzyloxy or phenylamino)-1,2,3,4-tetrahydroquinoline derivative, more specifically a tetrahydroquinoline compound represented by the general formula (1); [wherein R1, R2, R2', R3 and R3' independently represent a hydrogen atom, a C1-6 alkyl group, or the like; R4, R5, R6, R7, R8, R9 and R10 independently represent a hydrogen atom, a halogen atom, a C1-6 alkyl group, or the like; A represents N-R11 or an oxygen atom; R11 represents a hydrogen atom, a C1-6 alkyl group, or the like; and n represents an integer of 0 or 1], a salt of the tetrahydroquinoline compound, or a solvate of the tetrahydroquinoline compound or the salt.

  本文披露了一种具有促进EPO产生活性和/或增强血红蛋白表达活性的低分子化合物。具体披露了一种EPO产生促进剂和/或血红蛋白表达增强剂，包括1-酰基-4-(苯氧基、苄氧基或苯基氨基)-1,2,3,4-四氢喹啉衍生物，更具体地说是由通式（1）表示的四氢喹啉化合物；[其中R1、R2、R2'、R3和R3'独立地表示氢原子、C1-6烷基或类似物；R4、R5、R6、R7、R8、R9和R10独立地表示氢原子、卤素原子、C1-6烷基或类似物；A表示N-R11或氧原子；R11表示氢原子、C1-6烷基或类似物；n表示0或1的整数]，四氢喹啉化合物的盐，或四氢喹啉化合物或其盐的溶剂结晶体。
• Treatments for female sexual dysfunction and methods for identifying compounds useful for treating female sexual dysfunction
  申请人：——

  公开号：US20030083228A1

  公开（公告）日：2003-05-01

  The present invention provides a method of treating female sexual dysfunction, the method comprising the step of administering to a patent, having or at risk of having one or more of the disorders or conditions associated with female sexual dysfunction, a therapeutically effective amount of a compound that attenuates the binding of agouti-related protein to melanocortin receptors, but does not attenuate the binding of &agr;-melanocyte stimulating hormone to melanocortin receptors. The present invention also provides a method of identifying a compound that is useful for the treatment or prevention of female sexual dysfunction, the method comprising the steps of: 1) determining if a compound affects the binding of agouti-related protein to melanocortin receptors; 2) determining if a compound affects the binding of &agr;-melanocyte stimulating hormone to melanocortin receptors; and 3) selecting a compound that attenuates the binding of agouti-related protein to melanocortin receptors, but does not affect the binding of &agr;-melanocyte stimulating hormone to melanocortin receptors.

  本发明提供了一种治疗女性性功能障碍的方法，该方法包括向患有或有可能患有与女性性功能障碍相关的一种或多种疾病或病况的患者施用一种治疗有效量的化合物，该化合物减弱了agouti相关蛋白与黑素皮质素受体的结合，但不影响α-黑素细胞刺激激素与黑素皮质素受体的结合。本发明还提供了一种识别对治疗或预防女性性功能障碍有用的化合物的方法，该方法包括以下步骤：1）确定化合物是否影响agouti相关蛋白与黑素皮质素受体的结合；2）确定化合物是否影响α-黑素细胞刺激激素与黑素皮质素受体的结合；以及3）选择一种减弱agouti相关蛋白与黑素皮质素受体结合的化合物，但不影响α-黑素细胞刺激激素与黑素皮质素受体的结合。